(Q35917519)

11 August 2017

1 reference

title

Efavirenz for HIV-1 infection in adults: an overview (English)

1 reference

11 August 2017

1 reference

Claude Fortin

1

1 reference

11 August 2017

Veronique Joly

series ordinal

2

1 reference

11 August 2017

publication date

1 October 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

5

1 reference

11 August 2017

page(s)

671-684

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Rifampin and rifabutin drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

A manic episode associated with efavirenz therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Association between efavirenz and selected psychiatric and neurological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Periconceptional exposure to efavirenz and neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789072.2.5.671

21 January 2018

Identifiers

DOI

10.1586/14789072.2.5.671

1 reference

11 August 2017

1 reference